AstraZeneca: Imfinzi approved for lung cancer in China
(CercleFinance.com) - AstraZeneca has received marketing authorisation from China's regulators for its Imfinzi immunotherapy for the treatment of patients with unresectable, stage III non-small cell lung cancer, the company said on Thursday.
According to phase III results, Imfinzi reduced the risk of death by 32% and prolonged the time patients lived without disease progression or death by more than 11 months.
More than one-third of the world's lung cancer diagnoses and deaths occur in China.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
According to phase III results, Imfinzi reduced the risk of death by 32% and prolonged the time patients lived without disease progression or death by more than 11 months.
More than one-third of the world's lung cancer diagnoses and deaths occur in China.
Copyright (c) 2019 CercleFinance.com. All rights reserved.